KIT (CD117) Expression in a Subset of Non-Small Cell Lung Carcinoma (NSCLC) Patients

Abstract Background The study was done to investigate the effect of LncRNA MEG3 on the immunity and autophagy of non-small cell lung carcinoma through the IDO signaling pathway. Methods A total of 78 cases of early NSCLC patients (research group; RG) and 69 cases of health controls (control group; CG) during the same time were included. The contents of LncRNA MEG3 and miR-543 in peripheral blood and tissues and their diagnostic values for NSCLC were detected. The relationship between LncRNA MEG3 and miR-543 and their posttreatment contents and influence on the prognosis of NSCLC patients were tested. The expression of LncRNA MEG3, miR-543, and IDO (IDO1, IDO2, and TDO proteins) in the lung tissue of rats and the immune function in the CG and the RG were detected. The effects of LncRNA MEG3 and miR-543 on the biological behavior of NSCLC cells were determined. The role of LncRNA MEG3, miR-543, and IDO in NSCLC was verified. Results LncRNA MEG3 was low in peripheral blood and tissues, while miR-543 was high (P < 0.05); both had good diagnostic values for NSCLC (P < 0.05). LncRNA MEG3 had a negative correlation with miR-543 (P < 0.05) and influenced the prognosis of NSCLC patients (P < 0.05). LncRNA MEG3 in the lung tissue of rats using IDO inhibitor was elevated compared with that of lung carcinoma model rats (P < 0.05). The level of miR-543 was declined compared with that of lung carcinoma model rats (P < 0.05). The levels of IDO1, IDO2, and TDO proteins were evidently declined compared with those of lung carcinoma model rats (P < 0.05). Compared with lung carcinoma model rats, CD3+, CD4+, and CD4+/CD8+ of IDO inhibitor rats were elevated, while CD8+ was declined (P < 0.05). Cell proliferation and invasion ability and IDO1, IDO2, TDO, Beclin-1, and LC3-II proteins were declined in the sh-LncRNA MEG3 group (P < 0.05), while those in the mimics-miR-543 group were evidently elevated (P < 0.05). However, the double luciferase activity detection and RIP experiment confirmed that there was targeted regulation among them (P < 0.05). Conclusion MEG3 has low expression in NSCLC and affects the immunity and autophagy of NSCLC cells via regulating the miR-543/IDO signaling pathway, which is effective for the treatment of NSCLC.

Download Full-text

Identifying t cell profiles that associate with clinical response to anti-PD-1 treatment in non-small cell lung carcinoma (NSCLC) patients.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.e21239 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. e21239-e21239

Author(s):

Andre Kunert ◽

Edwin A. Basak ◽

Daan Hurkmans ◽

Yarne Klaver ◽

Mandy van Brakel ◽

...

Keyword(s):

T Cell ◽

Clinical Response ◽

Lung Carcinoma ◽

Small Cell Lung Carcinoma ◽

Small Cell ◽

Small Cell Lung ◽

Cell Lung Carcinoma ◽

Nsclc Patients

Download Full-text

Thymidine kinase 1 in serum for prognosis, an investigation on routine individual adapted treatment of non-small cell lung carcinoma.

10.21203/rs.2.10552/v1 ◽

2019 ◽

Author(s):

Zhongcheng Li ◽

Guoqing Zhang ◽

Jin Li ◽

Hongbo Ma ◽

Zhenxin Wang ◽

...

Keyword(s):

Thymidine Kinase ◽

Lung Carcinoma ◽

Small Cell Lung Carcinoma ◽

Clinical Stage ◽

Small Cell ◽

Small Cell Lung ◽

Thymidine Kinase 1 ◽

Cell Lung Carcinoma ◽

Hazard Risk ◽

Nsclc Patients

Abstract Background: Thymidine kinase 1 (TK1) is a key enzyme involved in DNA synthesis. The aim is to assess the prognostic significance of serum TK1 protein concentration (STK1p) and its role in monitoring of individual customized therapy in non-small cell lung carcinoma (NSCLC) patients in routine clinical setting. Methods: A prospective study of 129 NSCLC patients was confirmed by imager, /pathology and treated by radical resection (RR) combined with individual-chemotherapy or individual-chemotherapy alone, in 2010 to 2017. The STK1p was measured using an ECL dot blot assay in sera of patients. Results: Comparisons between 2-cycle-post-individual-chemotherapy and pre-individual-chemotherapy showed that STK1p was significantly associated with treatment effect (p<0.001), and the STK1p low-group correlated significantly to the early/middle clinical stage, as well as the treatment with RR+ individual-chemotherapy (p < 0.05). A significantly poor overall survival (OS) was found in elevated-risk STK1p vs. low-risk STK1p values (p=0.016), in advantage clinical stage vs. early/middle clinical stage (p=0.004), in SCC patients compare vs. AC patients (p=0.003) and in chemotherapy alone vs. RR combined with individual-chemotherapy (p=0.001). The multivariate analysis showed that STK1p (hazard risk=2.295, p=0.010), and RR combined with individual-chemotherapy (hazard risk=3.04, p=0.0001), were independently survival factors. Conclusions: STK1p correlates significantly to survival and is an independent multivariate prognostic factor in NSCLC patients. STK1p as a low-cost assay, is a useful tool to combine with imager for a rational approach to increase the efficacy in early detection of tumor in lung cancer screening and assessment of individual adjusted therapy in NSCLC patients.

Download Full-text

Prognostic Significance of N-Glycolyl GM3 Ganglioside Expression in Non-Small Cell Lung Carcinoma Patients: New Evidences

Pathology Research International ◽

10.1155/2015/132326 ◽

2015 ◽

Vol 2015 ◽

pp. 1-12 ◽

Cited By ~ 12

Author(s):

Rancés Blanco ◽

Elizabeth Domínguez ◽

Orlando Morales ◽

Damián Blanco ◽

Darel Martínez ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Lung Carcinoma ◽

Small Cell Lung Carcinoma ◽

Prognostic Significance ◽

Small Cell ◽

Small Cell Lung ◽

Cell Lung Carcinoma ◽

Epidermal Growth ◽

Nsclc Patients

The prognostic role of N-glycolyl GM3 ganglioside (NeuGcGM3) expression in non-small cell lung carcinoma (NSCLC) still remains controversial. In this study, the NeuGcGM3 expression was reevaluated using an increased number of NSCLC cases and the 14F7 Mab (a highly specific IgG1 raised against NeuGcGM3). An immunohistochemical score integrating the percentage of 14F7-positive cells and the intensity of reaction was applied to reassess the relationship between NeuGcGM3 expression, some clinicopathological features, and the overall survival (OS) of NSCLC patients. The double and the triple expression of NeuGcGM3 with the epidermal growth factor receptor (EGFR) and/or its ligand, the epidermal growth factor (EGF), were also evaluated. NeuGcGM3 expression correlates with both S-Phase fraction (p=0.006) and proliferation index (p=0.000). Additionally, NeuGcGM3 expression was associated with a poor OS of patients in both univariate (p=0.020) and multivariate (p=0.010) analysis. Moreover, the double and/or the triple positivity of tumors to NeuGcGM3, EGFR, and/or EGF permitted us to identify phenotypes of NSCLC with a more aggressive biological behavior. Our results are in agreement with the negative prognostic significance of NeuGcGM3 expression in NSCLC patients. However, standardization of techniques to determine the expression of NeuGcGM3 in NSCLC as well as the implementation of a universal scoring system is recommended.

Download Full-text

Prevalence and clinical associations of PTEN loss in non-small cell lung carcinoma (NSCLC) patients (pts) of the European Thoracic Oncology Platform (ETOP) Lungscape cohort

Annals of Oncology ◽

10.1093/annonc/mdw392.07 ◽

2016 ◽

Vol 27 ◽

pp. vi528

Author(s):

A. Soltermann ◽

U. Rulle ◽

O. Dafni ◽

E. Verbeken ◽

E. Thunnissen ◽

...

Keyword(s):

Lung Carcinoma ◽

Small Cell Lung Carcinoma ◽

Small Cell ◽

Small Cell Lung ◽

Cell Lung Carcinoma ◽

Pten Loss ◽

Clinical Associations ◽

Nsclc Patients

Download Full-text

Association of overexpressed MYC gene with altered PHACTR3 and E2F4 genes contributes to non-small cell lung carcinoma pathogenesis

Journal of Medical Biochemistry ◽

10.2478/jomb-2018-0022 ◽

2019 ◽

Vol 38 (2) ◽

pp. 188-195 ◽

Cited By ~ 3

Author(s):

Miodrag Dragoj ◽

Jasna Bankovic ◽

Ana Podolski-Renic ◽

Sonja Stojkovic Buric ◽

Milica Pesic ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Lung Carcinoma ◽

Small Cell Lung Carcinoma ◽

Small Cell ◽

Small Cell Lung ◽

Cell Lung Carcinoma ◽

Nsclc Patients ◽

Gene Alterations

Summary Background C-Myc is one of the major cellular oncogenes overexpressed in non-small cell lung carcinoma (NSCLC). Its deregulated expression is necessary but not sufficient for malignant transformation. We evaluated expression of MYC gene in NSCLC patients and its association with alterations in the genes previously identified to be related to NSCLC pathogenesis, PHACTR3 and E2F4. Methods We analyzed MYC gene expression by qRT-PCR in 30 NSCLC patients’ samples and paired normal lung tissue. MYC expression was further statistically evaluated in relation to histopathological parameters, PHACTR3 and E2F4 gene alterations and survival. Alterations in aforementioned genes were previously detected and identified based on AP-PCR profiles of paired normal and tumor DNA samples, selection of DNA bands with altered mobility in tumor samples and their characterization by the reamplification, cloning and sequencing. Results MYC expression was significantly increased in NSCLC samples and its overexpression significantly associated with squamous cell carcinoma subtype. Most importantly, MYC overexpression significantly coincided with mutations in PHACTR3 and E2F4 genes, in group of all patients and in squamous cell carcinoma subtype. Moreover, patients with jointly overexpressed MYC and altered PHACTR3 or E2F4 showed trend of shorter survival. Conclusions Overall, MYC is frequently overexpressed in NSCLC and it is associated with mutated PHACTR3 gene, as well as mutated E2F4 gene. These joint gene alterations could be considered as potential molecular markers of NSCLC and its specific subtypes.

Download Full-text